Gamma-glutamyl transferase-to-lymphocyte ratio as a prognostic marker in patients with hepatocellular carcinoma undergoing hepatectomy

doi:10.4240/wjgs.v17.i2.98578

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (487)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-3) series.

Item

Count

PDF

HTML

217

Figures (1-5)

Tables (1-3)

Sum=398

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=69

Feb 27, 2025 (publication date) through Feb 24, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Surg. Feb 27, 2025; 17(2): 98578
Published online Feb 27, 2025. doi: 10.4240/wjgs.v17.i2.98578

Full Size Figure Download Figure

Figure 4 Nomogram for predicting overall survival of patients with hepatocellular carcinoma after curative resection. GLR: Gamma-glutamyl transferase-to-lymphocyte ratio; MVI: Microvascular invasion; PLR: Platelet-to-lymphocyte ratio; TACE: Transarterial chemoembolization; TBIL: Total bilirubin.

Citation: Zhou PC, Huang R, Wang HT, Yang J, Peng JD, Fu ZX, Liao WJ, Ma HQ, Wu LQ, Li EL. Gamma-glutamyl transferase-to-lymphocyte ratio as a prognostic marker in patients with hepatocellular carcinoma undergoing hepatectomy. World J Gastrointest Surg 2025; 17(2): 98578
URL: https://www.wjgnet.com/1948-9366/full/v17/i2/98578.htm
DOI: https://dx.doi.org/10.4240/wjgs.v17.i2.98578